HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative analysis of the long-term outcomes of segmentectomy and lobectomy for stage IA1 lung adenocarcinoma in patients with or without previous malignancy of other organs: a population-based study.

AbstractBACKGROUND:
For early stage non-small cell lung cancer, whether limited resection can yield comparable outcomes to those of lobectomy hasn't been established. We compared Overall survival (OS) and lung cancer-specific survival (LCSS) after segmentectomy or lobectomy in stage IA1 (≤10 mm) lung adenocarcinoma (LUAD) patients.
RESEARCH DESIGN AND METHODS:
We retrospectively recruited patients who'd been diagnosed with lung cancer for the first time and treated with segmentectomy or lobectomy, with or without previous other malignancy.
RESULTS:
1788 patients were included. After propensity score matching: 5-year OS were 85.6% for segmentectomy and 84.7% for lobectomy (p=0.951); 5-year LCSS were 93.5% for segmentectomy; and 93.0% for lobectomy (p=0.726). Cox regression analysis revealed segmentectomy was comparable to lobectomy in OS and LCSS. Having a second lung cancer later in life was associated with a worse LCSS for lobectomy (p<0.05) rather than segmentectomy. After patients were stratified according to malignancy history, subgroup analyses showed no significant prognosis differences between two surgeries.
CONCLUSIONS:
For stage IA1 LUAD patients who were diagnosed with lung cancer for the first time, with or without previous other malignancy, segmentectomy yields comparable outcomes to those of lobectomy. It may provide better outcomes for patients with multiple suspicious nodules.
AuthorsWenliang Bai, Jiaqi Zhang, Yanqing Wang, Mengxin Zhou, Lei Liu, Guige Wang, Ke Zhao, Xuehan Gao, Shanqing Li
JournalExpert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 22 Issue 2 Pg. 215-228 (Feb 2022) ISSN: 1744-8328 [Electronic] England
PMID34596477 (Publication Type: Journal Article)
Topics
  • Adenocarcinoma of Lung (pathology, surgery)
  • Carcinoma, Non-Small-Cell Lung (pathology, surgery)
  • Humans
  • Lung Neoplasms (pathology, surgery)
  • Neoplasm Staging
  • Pneumonectomy
  • Retrospective Studies
  • SEER Program

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: